Study of Efficacy of Carbamazepine in Therapy of Patients With Moderate Persistent and Severe Bronchial Asthma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00153296 |
|
Recruitment Status :
Completed
First Posted : September 12, 2005
Last Update Posted : February 19, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bronchial Asthma | Drug: Carbamazepine | Phase 4 |
Effective therapy of asthma still remains quite serious problem. According GINA definition, asthma is an inflammatory disorder. Consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. But asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. Besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. But some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. Some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy.
We performed a double-blind, placebo-controlled 3-month trial for evaluation of carbamazepine efficacy in therapy of bronchial asthma. Carbamazepine is a well-known, comparatively safe and effective antiepileptic drug.
Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 68 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double |
| Primary Purpose: | Treatment |
| Official Title: | Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Carbamazepine Efficacy in Moderate Persistent and Severe Asthma Therapy |
| Study Start Date : | August 2004 |
| Study Completion Date : | April 2005 |
- At 3 months of treatment: Change from baseline of the FEV1 and PEFR (also %predicted); Number of patients without asthma symptoms
- At 3 months of treatment: FEV1 before and after salbutamol inhalation; Difference in PEF pm-am (in %); The daily (daytime and night-time) symptoms scores; % of symptom free days during the treatment period; Use of other antiasthmatic medication
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years to 65 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have given their informed consent before commencing the procedures specified in the protocol, indicating that they understand the objectives of the study and are willing to adhere to the procedures described in the protocol.
- Males or females.
- Patient aged between 16 and 65 years.
- Out patients.
- Non smokers or ex-smokers, having stopped smoking > 1 year.
- Moderate persistent or severe asthma, according GINA classification
- Patients with an established (i.e. at least one year) clinical history of asthma.
- Absence of long-term remissions of asthma (lasting more than 1 month)
- Poorly controlled asthma, due to various reasons.
- Patients with a FEV1 reversibility of at least 12% from initial level after 400 mcg salbutamol inhalation (4 puffs of salbutamol MDI, 100 mcg per puff). Patients whose FEV1 reversibility was 12% within the past 12 months are acceptable, providing that the records are available to the investigator.
- Patients able to swallow capsules, able to understand and complete diary cards and to record their PEFR using a peak-flow meter.
Exclusion Criteria:
- Long-term history of smoking (3 years and more)
- History or presence of cardiovascular, renal, neurologic, psychiatric, liver, immunologic, endocrine, infection or other diseases or dysfunctions if they are clinically significant. A clinically significant disease is defined as one which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.
- Patients with a recent history (< 1 year) of myocardial infarction and/or (< 3 years) of heart failure or patients with any cardiac arrhythmia requiring drug therapy.
- History of cancer within the past 5 years.
- Patients with active tuberculosis with indication for treatment.
- Patients with a history of cystic fibrosis, bronchiectasis, chronic bronchitis or emphysema.
- Patients with clinically significant abnormal baseline haematology, blood chemistry or urinalysis or if the abnormal defines a disease listed as an exclusion criterion.
- Patients with known allergy, side effects, intolerance/hypersensitivity to investigational drug
- Patients currently using MAO inhibitors, tricyclic antidepressants, antiepileptic drugs, narcotic agents.
- Pregnant or nursing women and sexually active women with childbearing potential not using a medically approved method of contraception.
- Patients unlikely, unable or unwilling to comply with the requirements of the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00153296
| Principal Investigator: | Merab Lomia, MD, PhD | "Rea" Rehabilitation Centre | |
| Study Director: | Tamuna Tchelidze, MD | CRO Evidence | |
| Study Chair: | Manana Tchaia, MD | Centre of Chinese Medicine |
Additional Information:
Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine
Publications of Results:
| ClinicalTrials.gov Identifier: | NCT00153296 History of Changes |
| Other Study ID Numbers: |
LTP-1004-CZ-0405 |
| First Posted: | September 12, 2005 Key Record Dates |
| Last Update Posted: | February 19, 2009 |
| Last Verified: | February 2009 |
|
Bronchial asthma Carbamazepine Antiepileptic drugs Efficacy |
|
Carbamazepine Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Anticonvulsants |
Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |